Table 1

Baseline characteristics

VariablesStandard
treatment arm
Programmed
treatment arm
Programmed treatment arm
(n=167)(n=170)TNF-low (n=51)TNF-int (n=68)TNF-high (n=51)
Age≥6559 (35.3)43 (25.3)9 (17.6)18 (26.5)16 (31.4)
65<108 (64.7)127 (74.7)42 (82.4)50 (73.5)35 (68.6)
Median (range)59 (20–83)58 (20–81)56 (20–76)58 (21–81)61 (34–78)
SexMale31 (18.6)41 (24.1)15 (29.4)12 (17.6)14 (27.5)
Female136 (81.4)129 (75.9)36 (70.6)56 (82.4)37 (72.5)
Duration of disease, years≥369 (41.3)71 (41.8)22 (43.1)28 (41.2)21 (41.2)
3<98 (58.7)99 (58.2)29 (56.9)40 (58.8)30 (58.8)
Median (range)1.6 (0.1–58.0)2.0 (0.2–36.83)1.8 (0.3–33.5)2.0 (0.2–36.8)2.0 (0.2–33.0)
Baseline SDAI≥2671 (42.5)74 (43.5)17 (33.3)29 (42.6)28 (54.9)
26<96 (57.5)96 (56.5)34 (66.7)39 (57.4)23 (45.1)
Median (range)24.3 (11.1–80)24.1 (11.1–108)20.5 (11.5–58)23.9 (11.1–67)31.1 (11.6–108)
Tender/painful joint countMedian (range)6 (0–28)7 (0–28)6 (0–24)5 (0–27)9 (1–28)
Swollen joint countMedian (range)6 (0–28)6 (1–23)6 (1–20)6 (2–23)7 (1–22)
Patients’ VASMedian (range)50 (4–100)50 (2–100)46 (9–98)50.5 (2–100)53 (7–100)
Physicians’ VASMedian (range)50 (12–100)47 (5–100)40 (5–84)48 (15–90)50 (9–100)
CRP, mg/dLMedian (range)0.91 (0.0–15.1)1.0 (0.0–20.7)0.76 (0.0–4.52)1.07 (0.0–9.08)1.30 (0.02–20.7)
Baseline DAS28-CRPMedian (range)3.97 (2.1–7.4)4.1 (1.6–6.9)3.68 (2.9–6.3)4.02 (1.6–6.78)4.37 (2.8–6.89)
Baseline DAS28–ESRMedian (range)5.27 (0.14–8.49)5.36 (1.2–8.33)4.98 (2.7–8.06)5.17 (0.36–8.33)6.02 (2.77–8.30)
Baseline TNF–α0.55<55 (32.9)51 (30.0)51 (100)00
0.55≤1.6561 (36.5)68 (40.0)068 (100)0
≥1.6551 (30.5)51 (30.0)0051 (100)
HAQ-DI scoreMedian (range)0.88 (0–3)0.88 (0–2.88)0.88 (0.0–2.38)0.88 (0.0–2.88)1.13 (0.0–2.63)
mTSSMedian (range)8.25 (0–318)8 (0–403)6.75 (0–403)8.5 (0–378)8.5 (0–151.5)
Rheumatoid factorMedian (range)45.2 (0–2301)59 (0–2050)59.5 (0–846)43.5 (0.19–810.8)77 (4–2050)
MTX doseMedian (range)10 (6–17.5)12 (6–16)12 (6–16)11 (6–16)10 (6–16)
  • CRP, C-reactive protein; DAS28-ESR, disease activity score in 28 joints using erythrocyte sedimentation rate; ESR, erythrocyte sedimention rate; HAQ, health assessment questionnaire; HAQ-DI, health assessment questionnaire-disability index; mTSS, modified total Sharp score; MTX, methotrexate; SDAI, simplified disease activity index; TNF-α, tumour necrosis factor α; VAS, visual analogue scale.